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Abstract 
 Background: Beta blockers are recommended by the American College of 
Cardiology/American Heart Association Guidelines for high and intermediate-risk 
cardiac patients undergoing non-cardiac surgery.  Beta blockers are a class of drugs that 
moderate the effects of increased catecholamine levels on the heart by selectively 
blocking beta receptors in the heart and blood vessels, resulting in a lower heart rate and 
blood pressure.  Beta blocker use perioperatively has been shown to reduce the risk of 
ischemia and infarction. 
 Purpose: The purpose of this project is to address beta blocker use in a group of 
anesthesia providers who routinely attend to high-risk and intermediate-risk cardiac 
patients undergoing non-cardiac surgery in a medium-sized private hospital in suburban 
South Florida. There are barriers to the implementation of the published guidelines for 
beta blocker administration, including lack of awareness of the best current practice and a 
lack of a formal beta blocker protocol at the institutional level.    
 Methods: A simple and inexpensive beta blocker protocol was implemented and 
evaluated by various means.   Beta blocker administration practices were examined and 
documented prior to and after protocol implementation. Beta blocker usage was 
examined prior to and after protocol implementation 
 Findings/Implications: It was hypothesized that increased anesthesia provider 
awareness would lead to increased administration of perioperative beta blockers to high-
risk and intermediate-risk cardiac patients undergoing non-cardiac procedures. Although 
viii 
there was a knowledge increase related to the new beta blocker protocol, no change in 
practice was observed. 
 
 
 
Chapter 1: Introduction 
Problem Identification 
According to published estimates, 27 million non-cardiac surgeries are performed 
in the United States annually; four to six percent of patients with cardiac disease or 
cardiac risk factors undergoing non-cardiac surgery will have a myocardial infarction 
(MI), up to 1% will have a stroke, and 2-3% will die of cardiac and non-cardiac causes 
(White et al., 2010).  The leading cause of postoperative morbidity and mortality is 
perioperative MI (Savio et al., 2011).  There is a mortality rate of 15-25% in patients 
having an MI after non-cardiac surgery and a mortality rate of 65% in patients having a 
cardiac arrest after non-cardiac surgery (Devereaux et al., 2005).  Perioperative 
complications can prolong hospital stays significantly, add to overall healthcare costs, 
and consume healthcare resources. 
 Beta blocker use perioperatively has been shown to reduce the risk of ischemia 
and infarction, and is recommended by the American Heart Association and the 
American College of Cardiology (Beckman et al., 2006) for patients already on beta 
blockers and high-risk patients having non-cardiac surgery.  The recommendations are 
not as clear for intermediate and low-risk patients (White et al., 2010).  Appropriate 
perioperative beta blockade in high-risk patients has been a national standard of care 
since 1996, although guidelines for implementation have been updated several times and 
continue to evolve (Wallace, Au, & Cason, 2010).  Not all institutions and anesthesia 
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providers follow this standard of care or the ACC/AHA guidelines consistently 
(Lindenauer et al., 2005). 
 
Abbreviated Literature Review 
Numerous trials have looked at the benefits and risks of beta blocker therapy in 
various patient populations.  A literature search was conducted using the search terms 
perioperative beta blockers and perioperative beta blocker protocols.  PUBMED and 
CINAHL were queried.  PUBMED returned 78 articles using the following limits:  
humans; clinical trials; meta-analyses; practice guidelines; English; MEDLINE; Adults 
19+; 1995-2011.  CINAHL returned 49 full text articles dated between 1995 and 2011.   
 Four random controlled trials (RCTs) evaluated the perioperative use of beta 
blockers in non-cardiac surgery; first, the Perioperative Ischemia Evaluation (POISE) 
looked at 8351 patients with a 30-day follow up; second, the Beta Blocker in Spinal 
Anesthesia (BBSA) looked at 219 patients with a 1-year follow-up; third, in the Atenolol 
Study, Mangano, Layug, Wallace, and Tateo (1996) looked at 200 patients with a 2-year 
follow-up; fourth, the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress 
Echocardiography (DECREASE), looked at 112 patients with a 30-day follow-up.  The 
Atenolol and DECREASE studies were influential in increasing perioperative beta 
blocker administration and this led to clinical practice guidelines, institutional 
benchmarking, and performance measures.  Not everyone was convinced that aggressive 
beta blockade was safe and effective; the Atenolol and DECREASE trials were both 
criticized for their small sample size, lack of placebo control, and the chosen method of 
statistical analysis (London, 2008).  White, et al. (2010) critiqued these four RCTs and 
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concluded that the use of beta blockers reduces the MI rate but increases the frequency of 
stroke, severe hypotension, and severe bradycardia.  Wallace et al. (2010) showed a 
significant association between perioperative beta blockade and postoperative survival in 
patients with existing indications for beta blockade. 
Historical Development of Guidelines 
The 1996 Atenolol Study provided evidence that perioperative beta blockers 
reduced mortality.  In 1998, Wallace et al. developed a protocol based on this evidence 
and called it the Perioperative Cardiac Risk Reduction Therapy (PCRRT); until its 
introduction, only patients in RCTs received perioperative beta blockers by study specific 
protocols.  The PCRRT protocol is simple and easy to follow and has been adopted by a 
number of hospitals and hospital systems (Wallace et al., 2010). 
 In 2001, the Agency for Healthcare Research and Quality (AHRQ) recommended 
the use of beta blockers to reduce perioperative cardiac events and mortality in high-risk 
patients undergoing non-cardiac surgery.  However, controversies remained in the 
literature regarding the use of beta blockers in patients of low or moderate risk having 
non-cardiac surgery (VanDenKerhof, Milne, & Parlow, 2003).  
 The American College of Cardiology and the American Heart Association Task 
Force on Practice Guidelines issued a 2006 focused update on perioperative beta blocker 
therapy in response to this therapy becoming a quality measure for the Physicians 
Consortium for Performance Improvement and the Surgical Care Improvement Project 
(Beckman et al., 2006).  The recommendations produced by the Task Force were 
intended for use in these national quality initiatives and contained three levels of 
evidence (A, B, and C), and three classes of recommendations (Class I; Class II, a and b; 
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and, Class III).  The focused update recommendations were integrated into the revised 
ACC/AHA guidelines on perioperative cardiovascular evaluation for non-cardiac surgery 
in 2009.  The 2009 ACC/AHA consensus guidelines state that there is a Class I 
recommendation to continue beta blockers in patients who are currently taking them and 
a Class IIa recommendation to start titrated beta blockers in patients with coronary artery 
disease or in intermediate to high-risk patients.  There is also a Class IIb recommendation 
for beta blockers in intermediate to low-risk patients, although the usefulness is uncertain 
(Eldrup-Jorgensen, 2011).       
Clinical Practice 
Anesthesia providers usually practice autonomously and are relatively free to 
implement evidence-based practices and clinical guidelines in the operating room (OR), 
limited only by the drugs and equipment available.  Limiting factors include available 
choice of beta blockers, lack of consensus in the literature regarding the best choice of 
beta blocker, and fear of possible iatrogenic complications (VanDenKerhof et al., 2003; 
Baxter & Kanji, 2007).  
The integration of a simple and inexpensive beta blocker protocol into routine 
clinical practice can lead to improved outcomes in select cardiac patients undergoing 
non-cardiac surgery (Armanious, Wong, Etchells, Higgins, & Chung, 2003; Baxter & 
Kanji, 2007; Wallace et al., 2010).  Successful protocol implementation requires clinician 
acceptance, participation, and evaluation (Baxter & Kanji, 2007).  Numerous protocols 
have been published in the anesthesia literature and implemented with varying degrees of 
success.  One such protocol implemented in the Ottawa Hospital, Ottawa, Canada, 
demonstrated that the standardization of a perioperative protocol to identify at-risk 
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patients coupled with heightened anesthesia provider awareness led to an increase in beta 
blocker use and a reduction in adverse cardiac events (Baxter & Kanji, 2007).  
The Problem 
Evidence exists to support the use of beta blockers in high-risk and intermediate-
risk cardiac patients undergoing certain non-cardiac procedures.  The purpose of this 
project was to address the use of beta blockers in a group of anesthesia providers, both 
certified registered nurse anesthetists (CRNAs) and medical doctor anesthesiologists 
(MDAs) who routinely attend to high-risk and intermediate-risk cardiac patients 
undergoing non-cardiac surgery in a medium-sized, private suburban hospital in the 
Southeastern United States.  The study was implemented and evaluated.  Beta blocker 
administration practices were examined and documented prior to and after protocol 
implementation.  It was hypothesized that increased anesthesia provider awareness of the 
ACC/AHA guidelines for beta blocker administration would lead to increased 
administration of beta blockers to high-risk and intermediate-risk cardiac patients 
undergoing non-cardiac procedures.  The PICO question used to identify the evidence for 
the project was “In anesthesia providers caring for cardiac patients undergoing non-
cardiac surgery how does an increase in awareness of ACC/AHA guidelines for 
perioperative beta blocker administration influence compliance and decrease major 
perioperative complications?” 
 
 
 
Definitions 
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Anesthesia Provider  
A certified registered nurse anesthetist (CRNA) is an advanced practice registered 
nurse (APRN) who has acquired graduate-level education and board certification in 
anesthesia.  A medical doctor anesthesiologist (MDA) is a medical doctor who has 
successfully completed an accredited residency program in anesthesia.  No board 
certification is necessary to practice.  
Risk 
The Revised Cardiac Risk Index (RCRI) is a clinical prediction rule for use 
during preoperative care for prediction major cardiac complications of non-cardiac 
surgery originally published in 1977; six equally weighted cardiovascular risk factors 
(high-risk surgery, history of ischemic heart disease, history of congestive heart failure, 
history of cerebrovascular disease, preoperative treatment with insulin, preoperative 
serum creatinine level >2.0 mg/dl) are scored one point each.  Low-risk is one point or 
less, moderate-risk is two points, high-risk is three or more points.  
Protocol 
Protocol is a document that describes in detail the plan for conducting a clinical 
study.  The study protocol explains the purpose and function of the study as well as how 
to carry it out.  It describes the objectives, design, methodology, statistical considerations, 
and organization of the clinical trial.  
Clinical Practice Guidelines  
Clinical practice guidelines are systematically developed statements to assist 
practitioner and patient decisions about appropriate health care for specific clinical 
circumstances (Institute of Medicine, 1990).  
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Summary 
In summary, Chapter One introduced the challenges/problems with beta blocker 
use, the potential benefits of using beta blockers, an abbreviated literature review, and a 
brief description of the proposed project.  Research questions used to search the literature 
and definitions were also provided. 
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Chapter Two: Review of the Literature 
In this chapter, a more thorough review of the literature is included.  The role of 
beta blockers in preventing perioperative cardiac events is examined, methods of risk 
identification and reduction are identified, literature supporting the use of perioperative 
beta blockers is evaluated, and a critical appraisal of the literature is presented.  A 
literature search was conducted using Medline, CINAHL, and PUBMED for high level 
evidence using the following key terms: perioperative beta blockers and perioperative 
beta blocker protocols.  Articles dating back to 1995 that had the key terms were 
reviewed. 
Role of Beta Blockers 
Beta blockers have been used clinically since the 1960s to treat hypertension, 
heart failure, and coronary artery disease.  They exert their beneficial anti-arrhythmic, 
anti-inflammatory, and anti-renin-angiotensin effects by blocking beta 1 and 2 receptors 
found throughout the body.  The major direct effects are heart rate reduction, which 
increases diastolic perfusion time; and reduced myocardial contractility, which reduces 
myocardial oxygen demand.  Beta blockers decrease sympathetic tone, which indirectly 
reduces inflammation and shear stress leading to stabilization of coronary plaques.  The 
physiological rationale for perioperative beta blockade is to reduce the stress state 
brought on by surgery with its associated fasting, anesthesia, intubation, extubation, pain, 
hypothermia, and bleeding (Devereaux et al., 2005).  This stress state involves increased 
cortisol and catecholamine levels leading to increases in heart rate, blood pressure, 
coronary artery shear stress, insulin deficiency, and free fatty acids.  These factors can all 
lead to increased oxygen demand and perioperative myocardial ischemia, which is 
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strongly associated with preioperative myocardial infarction (Devereaux et al., 2005). 
Beta blockers can attenuate both kinds of perioperative MIs;  those caused by an 
asymptomatic coronary plaque rupturing in patients with multiple risk factors for MI but 
no critical stenosis, and those with a fixed coronary stenosis leading to a predisposition to 
mismatch myocardial oxygen supply and demand.  Studies have shown that a significant 
proportion of fatal perioperative MIs are due to an increase in oxygen demand in the 
setting of fixed coronary stenosis (decreased supply) (Landesberg, 2003).  
Risk Identification 
The key to successful prevention of perioperative cardiac events in non-cardiac 
surgery lies with identifying patients at risk for these events and optimizing them before 
surgery.  Patients with active cardiac conditions need to be identified, evaluated, and 
treated before surgery.  Simple clinical markers can identify patients at increased risk for 
perioperative cardiac events.  The Revised Cardiac Risk Index is a common preoperative 
risk stratification strategy that has been validated in prospective studies and is based on 
the Lee Index (Lee et al., 1999).  Six equally weighted cardiovascular risk factors (high-
risk surgery, history of ischemic heart disease, history of congestive heart failure, history 
of cerebrovascular disease, preoperative treatment with insulin, preoperative serum 
creatinine level >2.0 mg/dl) are scored one point each. Perioperative cardiac 
complications with no risk factors are 0.4%, one risk factor 0.9%, two risk factors 7%, 
and three or more risk factors 11%.  The ACC/AHA algorithm for preoperative risk 
assessment can also be used to stratify cardiac patients undergoing non-cardiac surgery.  
It is limited in its validity as it was not derived from a prospective study and includes 
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judgments from committee members (expert opinions) (Devereaux et al., 2005).  Once 
perioperative risk has been quantified, risk mitigation can be considered. 
Prophylactic perioperative use of beta blockers in high-risk and intermediate-risk 
cardiac patients undergoing non-cardiac surgery may be protective and reduce the risk of 
perioperative cardiovascular complications.  The first RCT addressing the issue of 
perioperative beta blockers was conducted by Mangano et al. in 1996 (Mangano et al., 
1996).  The authors concluded that the perioperative administration of atenolol decreased 
perioperative ischemia and caused an increased rate of event-free survival at six months 
in 200 high-risk cardiac patients undergoing non-cardiac surgery.  As part of the 
Multicenter Study of Perioperative Ischemia Research Group, Dr. Wallace at UCSF-VA 
Medical Center developed a perioperative cardiac risk reduction therapy (PCRRT) using 
beta blockers and clonidine for those patients in whom beta blockers are contraindicated 
(BBAC).  Perioperative myocardial ischemia is a risk factor that can actually be 
modified, unlike fixed risk factors such as age, hypertension, peripheral vascular disease, 
diabetes, coronary artery disease, and hyperlipidemia.  Prophylactic beta blockers are one 
medical therapy that can modify and reduce the risk of perioperative cardiac morbidity 
and mortality by up to 90% (Wallace, 1998). 
Literature Review 
In appraising the literature, multiple levels of evidence were reviewed.  Articles 
on perioperative use of beta blockers ranging from case studies to systematic reviews 
were all appraised.  This paper reviews multiple levels of evidence; two randomized 
studies, and two combined meta-analysis and systematic reviews.  Two large, 
longitudinal cohort studies are also examined, as well as two expert reviews. 
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Randomized Controlled Studies 
 The Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress 
Echocardiography (DECREASE) study by Poldermans et al. (1999), examined 112 high-
risk patients undergoing major vascular surgery in a randomized, multi-center study.  
High-risk patients were identified by clinical risk factors and positive results on 
dobutamine stress echocardiography.  Patients were stratified to receive bisoprolol, a beta 
blocker (59 patients), or placebo (53 patients); the group randomized to bisoprolol had 
significant reductions in perioperative cardiac death and nonfatal MI.  The overall rate of 
the combined endpoint of nonfatal myocardial infarction and death from cardiac causes 
was 34% (95% CI, 21 to 48%) in the placebo group, compared to 3.4% (95% CI, 0 to 
8%) in the bisoprolol group.  The estimated relative risk of death in the bisoprolol group 
compared to the placebo group was calculated to be 0.09 (95% CI, 0.02 to 0.37) 
(P<0.001).  Statistical analysis methods were presented and were appropriate for the data. 
The high rate of serious perioperative events in the placebo group was considered 
consistent with other studies on similar high-risk patients.  The authors concluded that 
bisoprolol reduced the perioperative incidence of death from cardiac causes and nonfatal 
MI in high-risk patients undergoing major vascular surgery.  The limitations of this study 
included its lack of blinding, although no major differences were found by the authors in 
the major aspects of perioperative treatment across the eight institutions involved in the 
study; this lack of blinding may have contributed to reporting errors and bias on the part 
of the investigators.  The importance of this study was the decrease in death and other 
serious perioperative complication in high-risk patients. 
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The Perioperative Ischemic Evaluation (POISE) trial by Devereaux et al. (2006) 
was designed to investigate the effects of perioperative beta blocker use.  It was a large, 
random controlled trial that instituted a single large dose of oral, extended release 
metoprolol (a beta blocker) in 8,351 beta blocker naïve, at-risk patients in 190 hospitals 
in 23 countries (4,144 in the metoprolol group and 4,177 in the placebo group).  Study 
treatment was started 2-4 hours before surgery and continued for 30 days.  The 
prespecified primary outcome was a composite of cardiovascular death, nonfatal MI, and 
nonfatal cardiac arrest at 30 days after randomization.  Analyses were by intention to 
treat.  Statistical analysis methods were appropriate for the data and all 8,351 patients 
were included.  
The authors found statistically significant reductions in the primary outcomes of 
cardiac death, nonfatal MI, and cardiac arrest (hazard ratio 0.84, 95% CI 0.70-0.99; 
P=0.0399); this beneficial effect resulted from fewer MIs in the metoprolol group.  The 
beneficial effect was counterbalanced by an increase in stroke (hazard ratio 2.17, 95% CI 
1.26-3.74; P=0.0053) and non-cardiac death (hazard ratio 1.33, 95% CI 1.03-1.74; 
P=0.0317) in the beta blocker group versus the controls.  The authors concluded that the 
results of this trial provide evidence that perioperative beta blockers prevent nonfatal MIs 
but increase the risk of nonfatal stroke, and that the variable beneficial effects of beta 
blockers were correlated with risk assessment, as the incidence of perioperative 
complications was contingent upon the number of risk factors present (high-risk surgery, 
ischemic heart disease, congestive heart failure, cerebrovascular disease, insulin-
dependent diabetes, and renal failure).  Limitations to the study included the possible 
inappropriate (both the dosage and the timing of administration) acute administration of 
 13 
high-dose beta blocker therapy to beta blocker naïve patients.  This study points out the 
importance of risk stratification and the beneficial effects of beta blockers in at-risk 
patients undergoing non-cardiac surgery. 
Systematic Reviews and Meta-Analyses 
 Devereaux et al. (2005) published a systematic review to determine the 
effectiveness of perioperative beta blocker treatment in patients having non-cardiac 
surgery.  Using seven search strategies, they identified twenty-two trials that randomized 
a total of 2,437 patients.  Eligibility criteria included perioperative outcomes within thirty 
days of surgery, total mortality, cardiovascular mortality, nonfatal MI, nonfatal stroke, 
nonfatal cardiac arrest, hypotension needing treatment, bradycardia needing treatment, 
and bronchospasm.  Two researchers independently evaluated study eligibility (k=0.96) 
and abstracted data (k=0.69-1.0).  Outcomes were defined as above plus the composite 
outcome of major perioperative cardiovascular events (cardiovascular death, nonfatal MI, 
nonfatal cardiac arrest).  Perioperative beta blockade did not show any statistically 
significant beneficial effects on any of the individual outcomes, but did show a 
significant beneficial relative risk of 0.44 (95% CI 0.20-0.97) for the composite outcome 
of cardiovascular mortality, nonfatal MI, and nonfatal cardiac arrest.  
  The stated strengths of the review were the multiple search strategies used to 
identify RCTs, verification of the data with all trialists, and evaluation of the reliability 
and conclusiveness of the available evidence using formal interim monitoring boundaries. 
The stated weaknesses of the review were the focus on short-term (30 day) outcomes, as 
it is possible that perioperative beta blockers affect long term outcomes, and the 
heterogeneity of the included studies, which weakens the reliability of the findings.  The 
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authors concluded that their review provides encouraging evidence that perioperative beta 
blockers may reduce the risk of major cardiovascular events during the perioperative 
period.  However, the evidence seems too unreliable to draw definitive conclusions.  This 
is an important review as it supports the use of beta blockers in high-risk patients 
undergoing non-cardiac surgery. 
  A more recent systematic review and meta-analysis was conducted by Savio et al. 
in 2011.  The authors searched electronic databases for RCTs of the perioperative use of 
esmolol (a short-acting intravenous beta blocker) in non-cardiac surgery.  Statistical 
heterogeneity was assessed primarily by meta-regression.  Their search identified 67 
trials of 3,766 patients undergoing non-cardiac surgery.  Data was extracted from the 
selected trials by two reviewers and included patient characteristics, study quality, drug 
dosages, methods of administration, changes in vital signs, and incidence of unplanned 
hypotension, bradycardia, myocardial ischemia, MI, and death.  The quality of the studies 
was limited by small sample size and poorly defined allocation concealment.  In the 
seven trials reporting the effect of esmolol on the magnitude and frequency of myocardial 
ischemia, it was found to decrease the frequency of myocardial ischemia in comparison 
with placebo (OR 0.17, 95% CI 0.02-0.45 p<0.001).  The effects of esmolol on the 
incidence of perioperative MI or stroke were not assessed because these events were too 
infrequent in the retrieved studies.  In the 67 studies, there were 6 documented MIs and 
no reported strokes. 
  The stated strengths of the review were: scrutinizing the text of each study for all 
adverse effects; including all adverse effects in the primary analysis; contacting all 
selected authors for missing information, unpublished data, or clarification of the results. 
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The effect of study quality on the outcome was compared using trial size, allocation 
concealment, and blinded outcome adjudication.  The stated weaknesses of the review 
were: the quality of the included studies was mixed; the sample sizes were generally 
small (the median size was 40 patients); 4 studies had no blinding protocol; allocation 
concealment was only reported in 5 studies; 10 studies did not conduct an intention-to-
treat analysis.  The authors concluded that esmolol has the potential to be both a safe and 
effective drug by providing protection against myocardial ischemia in patients 
undergoing non-cardiac surgery.  This is an important conclusion as esmolol is readily 
available perioperatively, has a rapid onset and a short half-life, and can be titrated to the 
desired effect.  The authors also recommended further studies of esmolol use in high-risk 
patients to establish a perioperative safety and efficacy profile for esmolol. 
Cohort Studies 
Lindenauer et al. (2005) conducted a retrospective cohort study of 782,969 
patients, 18 years or older, who underwent major non-cardiac surgery in 329 hospitals 
throughout the United States between 2000 and 2001.  The data was extracted from 
Premier’s Perspective, a database developed for measuring the quality and use of 
healthcare.  The authors used propensity-score matching to adjust for differences between 
those who received beta blockers and those who did not, and compared in-hospital 
mortality using multivariable logistic modeling.  They concluded that the relationship 
between perioperative beta blocker treatment and the risk of death varied directly with 
cardiac risk.  Among the 580,665 patients with a RCRI score of 0 or 1, treatment was 
associated with no benefit and possible harm.  Among the patients with a RCRI score of 
2, 3, or 4 or more, the adjusted odds ratio for death in the hospital for each was 0.88 (95% 
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CI, 0.80 to 0.98), 0.71(95% CI, 0.63 to 0.80), and 0.58(95% CI, 0.50 to 0.67), 
respectively.  This study showed that beta blockers were clearly beneficial in moderate 
and high-risk patients (two or more risk factors) undergoing major non-cardiac surgery, 
and that there was no benefit and possible harm in low-risk patients (less than two risk 
factors).  The authors concluded that ongoing national efforts to increase patient safety by 
increasing the perioperative use of beta blockers appear warranted as the use of beta 
blockers was associated with a reduced risk of death in the hospital among at-risk patients 
undergoing major non-cardiac surgery. 
Wallace et al. (2010) conducted an epidemiological analysis of 38,799 operations 
performed at the San Francisco VA Medical Center between 1996 and 2008.  Four 
patterns of beta blocker use were identified: none, addition, withdrawal, and continuous. 
Logistic regression, survival analysis, and propensity analysis were performed.  The 
perioperative addition of a beta blocker to the medical management of patients with 2 or 
more risk factors was associated with improved 30 day (OR 0.52, 95% CI 0.33-0.83, 
p=0.0006) and 1 year survival (OR 0.64, 95% CI 0.51-0.79, p=0.0001), as was the 
continuous use of beta blockers (30 day OR 0.68, 95% CI 0.47-0.98, p=0.04) (1 year OR 
0.82,95% CI 0.67-1.0, p=0.05) in patients already on them, during the perioperative 
period compared to patients receiving none.  Withdrawal of beta blockers during the 
perioperative period resulted in increased risk for 30 day (OR 3.93, 95% CI 2.57-6.01, 
p=0.0001) and 1 year (OR 1.96, 95% CI 1.49-2.58, p=0.0001) mortality.  The authors 
found that undertreatment with beta blockers is still common, and that prospective risk 
assessment and treatment with beta blockers could potentially reduce perioperative 
mortality further still.  The authors also found that the association between the risk of 
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death and perioperative beta blocker treatment varied with cardiac risk; patients without 
identifiable cardiac risk had no benefit and possible harm from perioperative beta 
blockers.  
Expert Reviews 
 An expert review by Flu et al. (2009) provided an extended overview of leading 
observational studies, meta-analyses, RCTs, and guidelines assessing perioperative beta 
blocker therapy.  The authors summarized the studies, guidelines, and meta-analyses to 
allow readers to place their strengths and weaknesses into perspective.  They identified 
the key issues: patients undergoing major non-cardiac surgery are at high risk for 
cardiovascular morbidity and mortality; the majority of cardiac events in patients 
undergoing major vascular surgery are asymptomatic; the high frequency of perioperative 
cardiac complications reflects the high incidence of underlying coronary artery disease. 
Treatment recommendations based on the current literature and the experience of the 
authors were provided.  They proposed that all intermediate and high-risk patients 
undergoing high-risk vascular procedures be treated with low-dose beta blockers, ideally 
started 30 days before surgery.  The goal of the beta blocker therapy should be to achieve 
a heart rate of between 65-70 beats per minute.  Withdrawal of beta blocker therapy 
shortly before surgery or in the immediate postoperative period was strongly discouraged, 
as it may lead to adverse myocardial effects.  They concluded that adequate heart rate 
control by beta blockers exerts a beneficial effect towards postoperative morbidity and 
mortality. 
 A second expert review was published in 2010 by White et al. to describe the 
benefits and risks associated with the use of beta blockers in non-cardiac surgery.  It was 
 18 
aimed at pharmacists to provide brief advice on how to handle specific drug therapy 
problems as part of a clinical consultation series.  The stated purpose of the article was to 
critique key RCTs and meta-analyses evaluating the perioperative use of beta blockers in 
non-cardiac surgery.  According to the authors, the choice of articles to critique was 
based on a systematic review of the literature and included the POISE and the 
DECREASE trials described above.  The authors concluded that the use of perioperative 
beta blockers in non-cardiac surgery can protect against postoperative MI but may 
increase the risk of hypotension, bradycardia, and stroke. 
Conclusion 
Based on the findings of this literature review, the existing consensus is that beta 
blockers should be used perioperatively in high and intermediate-risk cardiac patients 
undergoing major non-cardiac surgery.  
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 Chapter Three: Methodology  
The purpose of this evidenced-based project was to evaluate the effectiveness of a short 
training program for anesthesia providers to increase their use of beta blockers in high 
and intermediate-risk cardiac patients undergoing non-cardiac surgery.  The project 
design is an interventional one-group pre-test, post-test study. The research questions 
were as follows:  
1. Was there a change in the percentage of anesthesia providers using beta  
blockers before and after the PowerPoint intervention? 
2. Was there a change in the perception of anesthesia providers regarding the use  
of perioperative beta blockers before and after the PowerPoint intervention? 
3. Was there a change in the amount of beta blockers used perioperatively before 
and after the PowerPoint intervention? 
 
Sample 
 A convenience sample of anesthesiologists and certified registered nurse 
anesthetists at a medium-sized hospital in suburban south Florida were asked to 
participate. 
Methods 
This interventional, one-group pre-test post-test study design consisted of the 
following: 
1. The primary investigator conducted a retrospective review of the pharmacy  
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records to quantify beta blocker usage during the perioperative period.  The 
time frame for the review was the 3-month period immediately preceding the 
pre-test and planned intervention. 
2. All Health Insurance Portability and Accountability Act information was  
honored.  Data on individual patients was used in aggregate form only. 
3. All eligible anesthesia providers completed a pre-test, a post-test, and viewed 
a PowerPoint presentation on patient selection for beta blocker administration.  
4. Pharmacy records for the 3-month  period of time following the intervention  
were assessed for the quantity of beta blockers administered to patients in the 
perioperative period.  The outcome of interest was the increase in use of beta 
blockers in perioperative patients after the intervention.  This outcome was 
evaluated 3 months after the participants viewed the PowerPoint  presentation. 
Setting 
  The study took place at a large suburban hospital in South Florida.  This hospital 
is a private, 450 bed full-service facility that has been providing a range of healthcare 
services to residents of Fort Lauderdale, Florida for over 50 years.  It is fully accredited 
by the Joint Commission and specializes in comprehensive adult medical care, orthopedic 
surgery, bariatric surgery, a complete range of cardiovascular services, and maternal and 
newborn care. 
Data Collection and Evaluation 
Once Institutional Review Board (IRB) approvals and written consents were 
obtained, participants were asked to complete an anonymous one-page pre-intervention 
questionnaire on their knowledge and practice regarding perioperative use of beta 
 21 
blockers.  When all questionnaires were completed, a 25-slide PowerPoint was emailed to 
all eligible anesthesia providers outlining the use of beta blockers in cardiac patients 
undergoing non-cardiac surgery.  This evidence-based intervention was designed to give 
the anesthesia providers the best information about perioperative beta blocker use.  The 
intended outcome of this intervention was to increase the use of beta blockers at this 
facility thereby improving patient outcomes.  This project took place over 3 consecutive 
months.  Final data collection was completion of the same anonymous questionnaire 3 
months following the pre-intervention questionnaire.  The data collected on beta blocker 
usage during the 3-month study period was compared to beta blocker usage for the 3 
months immediately preceding the pre-intervention questionnaire. 
Feasibility and Resources 
The resources needed to ensure project completion include the facility keeping 
beta blockers stocked in the operating rooms, the pre-anesthesia area, and the post-
anesthesia care unit.  Medications were charged to the patient so that there were usually 
no budgetary considerations.  As beta blockers cost much less that the cost of treating a 
perioperative MI, this financial plan justified the need, feasibility, and sustainability of 
the proposed project. 
Institutional Review Board 
Institutional Review Board (IRB) approval was obtained from both the University 
of North Florida (UNF), and the participating clinical site through Western Institutional 
Review Board (WIRB).  Once both IRBs formally approved, data collection began.  All 
data was collected anonymously and handled in an aggregate manner.  There was no need 
to connect participant responses from pre-test to post-test, so there was no master list or 
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any identifying information.  Prior to starting the project, signed consent was obtained, 
scanned into UNF’s secure server, then shredded and discarded.  There was no link 
between consent and participant responses.  The raw data will be kept for three years. 
Data Analysis 
  Raw data was entered into Vovici at UNF, and checked for errors.  Analysis was 
performed using SPSS statistical software (version 16.0, 2005, Chicago, IL) with 
statistical significance determined at p<0.05.  Descriptive statistics were also used.  The 
Wilcoxon Signed-Rank Test was performed in order to examine between group 
differences in the use of beta blockers from pre-test to post-test.  This evidence-based 
practice project looked to see if there was a change in overall anesthesia practice with 
regard to beta blocker administration.  In the event that participants dropped from the 
study, it did not impact the project since only overall change was measured.  This change 
in practice was quantified by comparing beta blocker usage for the 3 months preceding 
the intervention with usage for the 3 months after the intervention by examination of 
pharmacy records. 
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     Chapter Four: Results 
 This chapter describes the study population using mean scores and frequency of 
the variables.  Analyses were executed using SPSS statistical software (version 16.0, 
2007, Chicago, IL) with statistical significance determined at p ≤0.05.  Data were 
analyzed using descriptive statistics and the Wilcoxon Signed-Rank Test to determine 
group differences between pre-test to post-test assessments. 
 A total of 19 anesthesia providers participated in this evidence-based practice 
project; 16 were male (78.9%) and 3 were female (21.1%).  No provider was under age 
30, three (15.8%) were 30-39, seven (36.8%) were 40-49, six (31.6%) were 50-59, and 
three (15.8%) were over 60.  Three providers had been in practice for 5 years or less 
(15.8%), two providers had been in practice 5-10 years (10.5%), two providers had been 
in practice 10-15 years (10.5%), seven providers had been in practice 15-20 years 
(36.8%), and five providers had been in practice over 20 years (26.3%).  
Pre-Intervention Results 
At the beginning of the study period all of the anesthesia providers were aware of 
studies in the literature related to prophylactic perioperative beta blocker use in cardiac 
surgical patients undergoing non-cardiac surgery who are at risk for cardiac 
complications (100%).  Only five providers (26.3%) were aware of the anesthesia 
department protocol for prophylactic beta blocker blockade in patients scheduled for non-
cardiac surgery who are at risk for cardiac complications.  Eight providers (42.1%) were 
not aware, and six providers (31.6%) were not sure if there was a department protocol.  A 
risk assessment tool was used by three providers (15.8%) all the time, six providers 
(31.6%) frequently, six providers (31.6%) occasionally, and four providers (21.1%) never 
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used a risk assessment tool.  Opinions on the prophylactic administration of beta blockers 
to patients with known coronary artery disease and patients with two or more risk factors 
for coronary artery disease differed: fourteen providers (73.7%) strongly agreed, and five 
providers (26.3%) mildly agreed that prophylactic beta blockers have an effect on 
postoperative outcomes; eleven providers (57.9%) strongly agreed, five providers 
(26.3%) mildly agreed, and three providers (15.8%) neither agreed nor disagreed that 
prophylactic beta blockers have an effect on postoperative outcomes in patients that have 
two or more risk factors for coronary artery disease.  
Post-Intervention Results 
 Seventeen of the original nineteen participants filled out the post-test 
questionnaire.  Two anesthesia providers resigned and relocated elsewhere during the 
study period.  At the end of the study period, five providers (29.4%) were aware of the 
department protocol for perioperative beta blocker administration, eight providers 
(47.1%) were not aware, and four providers (23.5%) were not sure.  A risk assessment 
tool was used by three providers (17.6%) all of the time, six providers (35.3%) 
frequently, four providers (23.5%) occasionally, and four providers (23.5%) never. 
Opinions on the prophylactic administration of beta blockers to patients with known 
coronary artery disease and patients with two or more risk factors for coronary artery 
disease differed: fourteen providers (82.4%) strongly agreed, and three providers (17.6%) 
mildly agreed that prophylactic beta blockers have an effect on postoperative outcomes; 
twelve providers (70.6%) strongly agreed, three providers (17.6%) mildly agreed, and 
two providers (11.8%) neither agreed nor disagreed that prophylactic beta blockers have 
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an effect on postoperative outcomes in patients that have two or more risk factors for 
coronary artery disease.  
Beta Blocker Inventory 
 A total of 211 doses of beta blockers (esmolol and metoprolol) were dispensed in 
the perioperative setting (not including the cardiac operating rooms) between March 21, 
2012 and June 21, 2012, comparable to 220 doses dispensed during the study period of 
June 22, 2012 through September 21, 2012.  The perioperative setting is comprised of the 
OR Holding area, where all surgical patients are prepared for surgery; the 16 non-cardiac 
operating rooms in the Main OR; and the PACU (post anesthesia care unit), where all 
surgical patients, except post-open heart patients, are recovered.  The increase of nine 
doses of beta blockers is not statistically significant (p>0.05), nor is it clinically 
significant. 
Conclusion 
The results indicate that all of the anesthesia providers were aware of studies in the 
literature related to prophylactic perioperative beta blocker use in cardiac surgical 
patients undergoing non-cardiac surgery who are at risk for cardiac complications. This 
knowledge and the 25-slide PowerPoint intervention were unsuccessful in changing 
provider practice as there was no increase in the number of beta blockers used or in the 
use of a risk assessment tool. There was also no increase in provider awareness about the 
beta blocker protocol that was implemented. 
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Figure 4.1.  Protocol Awareness. 
 
 
 
 
Figure 4.2.  Beta Blockers Dispensed 
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Figure 4.3  Risk Assessment Tool Use. 
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Chapter Five: Discussion 
This chapter provides a discussion of the anesthesia providers’ use of 
perioperative beta blockers, interventions to promote beta blocker usage, and lessons 
learned in the process.  Implications for evidence-based practice and future research are 
also presented. 
Discussion of Use of Beta Blockers 
This evidence-based project did not produce the results that this investigator 
expected; there was no change in the percentage of anesthesia providers using beta 
blockers before and after the PowerPoint intervention. This conclusion was supported by 
the absence of any increase in beta blockers dispensed during the study period and by the 
comparison of pre-test usage to post-test usage (figure 4.2).  
There was no change in the perception of anesthesia providers regarding the use 
of perioperative beta blockers before and after the PowerPoint intervention.  There was 
no change in awareness of a departmental beta blocker protocol noted in the post-test 
compared to the pre-test despite the introduction of a written beta blocker order set and 
risk assessment tool (figure 4.3) as part of the anesthesia preoperative orders. There was 
no change in provider perception about the use of beta blockers in high and intermediate-
risk patients noted in the post-test compared to the pre-test (figure 4.1).  
There was no statistically significant change in the amount of beta blockers 
dispensed perioperatively during the study period compared to the previous 90 days. The 
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PowerPoint presentation seemed to have no effect in increasing the use of beta blockers 
in the perioperative period.  
Interventions 
 The study intervention consisted of a 25-slide PowerPoint presentation outlining 
the rationale for beta blocker use in high and intermediate risk cardiac surgical patients 
undergoing high and intermediate risk non-cardiac surgery.  This presentation was 
supplemented by a new pre-printed preoperative order set that included a risk assessment 
tool and an easy check-box beta blocker order set.  This order set was introduced at the 
beginning of the study period and has become the default preoperative order set (pre-
anesthesia orders before the study period and during the study period). 
The implementation of the protocol was facilitated by the Chief of Anesthesia on 
the day my project began. At the Department of Anesthesia bi-weekly meeting he passed 
out the new pre-anesthesia order set that I created, which incorporates a risk assessment 
tool along with easy to use checkboxes to facilitate beta blocker orders preoperatively. 
The new and old order sets are in the Appendix. Because of the dynamics of the work 
environment, it was felt that the introduction was best handled by him as a Departmental 
initiative. 
Lessons Learned 
 More than a 25-slide PowerPoint is needed to change anesthesia providers’ 
awareness of beta blocker usage in cardiac patients undergoing high and medium-risk 
non-cardiac surgery.  Facilitating this awareness with an easy-to-use preprinted order set 
was not sufficient to change practice. Reinforcement by including a risk assessment tool 
on the preprinted order set was also not sufficient to change provider practice.  
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A more positive result may have been obtained with stronger buy-in from the 
Department of Anesthesia leadership. Other strategies to improve increases in beta 
blocker usage in appropriate patients could include a presentation at a Department 
meeting followed by a group discussion about proper patient selection. Reinforcement 
could also include a checkbox on the anesthesia record concerning beta blocker status. 
Strengths and Weaknesses 
 The strength of this project is the application of evidence-based knowledge of 
perioperative beta blocker usage in cardiac surgical patients undergoing non-cardiac 
surgery to improve postoperative outcomes and decrease morbidity and mortality.  The 
major weakness of the project was the small number of participants (19), the short 90-day 
duration of the study period, and the distinct possibility that the participants did not view 
the 25-slide PowerPoint that outlined the evidence supporting perioperative beta blocker 
usage in cardiac patients undergoing high and medium-risk non-cardiac surgery. 
Clinical Practice Implications  
Results indicate that heightened awareness of anesthesia providers did not occur 
and did not lead to increased beta blocker use perioperatively.  Controversy about patient 
selection criteria for perioperative beta blockade remains.  The evidence and the 
ACC/AHA guidelines are clear for high-risk and low-risk patients.  Even with risk-
assessment tools, it is not always clear which medium-risk patients will benefit from beta 
blockers. The ACC/AHA guidelines for medium-risk patients are nonspecific and leave it 
up to the individual provider to determine if the benefit of beta blocker administration 
outweighs the risk of adverse outcomes such as hypotension, bradycardia and stroke. 
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Further clarification of the guidelines for medium-risk patients could promote increased 
utilization of beta blockers in this patient population.  
The participants in this study were all aware (100%) of the published literature on 
the benefits of beta blocker therapy, but not all have incorporated this knowledge into 
their practice. This may be due to individual reluctance to interpret national guidelines 
and apply them clinically. It may also be due to their desire to not harm patients that may 
not benefit from the administration of beta blockers. 
Future Directions for Research 
 This investigator will seek to continue and expand this evidence-based project by 
participating in the creation of a hospital-wide beta blocker order set as part of a new 
computer physician order entry (CPOE).  Another reinforcement strategy will be the 
introduction of a patient’s beta blocker status into the verbal time-out that is routinely 
performed right before any procedure starts.  This confirmation of beta blocker status is 
already a part of the verbal time out for all cardiac procedures and could be extended to 
include all cardiac patients undergoing non-cardiac procedures.   
More studies are needed to provide better evidence about the benefits of beta 
blockers in high and intermediate risk cardiac patients undergoing high and intermediate 
risk non-cardiac surgery.  As evidence accumulates indicating better patient outcomes 
when beta blockers are used appropriately, anesthesia providers may be more willing to 
change their practice by incorporating this evidence. These studies should be large, multi-
center prospective random controlled trials to validate the use of beta blockers in high 
and intermediate-risk cardiac patients undergoing noncardiac surgery. It would be 
especially important for these studies to focus on the kinds of beta blockers, doses, 
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routes, and timing of administration that would optimize positive patient outcomes in this 
particular patient population.  
Conclusion 
 This evidence-based project has shown that no change in practice occurred after 
dissemination of the best and most recent clinical evidence on perioperative beta blocker 
administration to cardiac patients undergoing non-cardiac surgery.  Other strategies will 
need to be developed to increase anesthesia provider awareness, as well as to facilitate 
beta blocker use in appropriate patients with the goals of improving clinical outcomes 
and decreasing morbidity and mortality in this patient population. 
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Appendix A: Consent to Participate 
 
 
Dear Participant, 
 
 My name is Jody Heriot and I am a graduate student at the University of North 
Florida. I am conducting research regarding the perioperative use of beta blockers. This 
study will attempt to determine the perceptions of anesthesia providers regarding the use 
of a perioperative beta blocker protocol before and after a PPT presentation designed to 
provide information regarding the use of beta blockers in cardiac patients undergoing 
non-cardiac surgery. 
If you take part in my project, you will be asked to complete a survey, view a short PPT 
presentation and complete a second survey. I will also be reviewing aggregate pharmacy 
records to evaluate any changes in beta blocker usage during the study period. . This 
project has been fully approved by the Institutional Review Boards of both the University 
of North Florida and Holy Cross Hospital. 
Participation in this study will take less than 30 minutes of your time over a 3 month 
period. Your responses will be anonymous. No one other than Jody Heriot will see your 
responses and your responses cannot be tied back to you. Although there are no direct 
benefits to you or compensation for taking part in this study, others may benefit from the 
information I find from the results of this study. Additionally, there are no foreseeable 
risks for taking part in this project. Participation is voluntary with no penalties for not 
responding to the questionnaire or ceasing participation. If you choose not to take part or 
to withdraw from this study, there will be no penalty or loss of benefits to which you 
would otherwise receive. 
If you have any questions or concerns about this project, please contact me or my 
professor. If you have questions about your rights as a participant, you may contact the 
University of North Florida’s Institutional Review Board Chairperson, Dr. Katherine 
Kasten, at 904-620-2498. 
Thank you for your consideration. 
Sincerely, 
Jody Heriot, CRNA    Gerard Hogan, CRNA (Project Committee 
Chair)  
Phone: 954-849-5808    Phone (904) 252-0937 
mothermuffet@aol.com   gerard.hogan@unf.edu 
 ________________________________________ (print name) attest that I am at least 
18 years of age and agree to take part in this study. A copy of this form was given to me. 
  
Signature: ______________________________________ Date: __________________ 
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Appendix B: Beta Blockers and Surgical Outcomes Questionnaire 
 
 
 
Please circle the most appropriate letter for each question. 
1. Are you aware of studies in the literature related to prophylactic perioperative beta blocker use 
in patients undergoing non-cardiac surgery who are at risk for cardiac complications? 
a) YES 
b) NO 
 
2. In your opinion does prophylactic perioperative administration of beta blockers in patients with 
known coronary artery disease, who are not already on regular beta blockers, have an effect on 
postoperative outcomes? 
a) STRONGLY AGREE 
b) MILDLY AGREE 
c) NEITHER AGREE NOR DISAGREE 
d) MILDLY DISAGREE 
e) STRONGLY DISAGREE 
 
3. In your opinion does prophylactic perioperative administration of beta blockers in patients with 
2 or more risk factors for coronary artery disease, who are not on regular beta blockers, have an 
effect on postoperative outcomes? 
a) STRONGLY AGREE 
b) MILDLY AGREE 
c) NEITHER AGREE NOR DISAGREE 
d) MILDLY DISAGREE 
e) STRONGLY DISAGREE 
 
4. Does your department have a protocol for prophylactic perioperative beta blockade in patients 
scheduled for non-cardiac surgery who are at risk for cardiac complications? 
a) YES 
b) NO 
c) DON’T KNOW 
 
5. How often do you use prophylactic beta blockers, as a routine part of perioperative care, in at-
risk patients with known coronary artery disease or 2 or more risk factors for CAD? 
a) ALWAYS                                             
b) USUALLY                                           
c) SOMETIMES                                        
d) SELDOM                                             
e) NEVER  
                                                
6. Approximately how many times in an average week would you administer prophylactic beta 
blockers? 
a) 0 
b) 1–2 TIMES 
c) 3–5 TIMES 
d) 5–10 TIMES 
e) >10 TIMES 
 
7. When do you generally start prophylactic beta blocker therapy? 
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a) BEGIN SEVERAL DAYS AHEAD OF SURGERY IN OUTPATIENT CLINIC 
b) MULTIPLE DOSES PREOP FOR INPATIENTS 
c) SINGLE PREOP DOSE 
d) POSTOPERATIVELY 
 
8. How long do you generally continue prophylactic beta blocker therapy? 
a) PREOPERATIVELY ONLY 
b) EARLY POSTOPERATIVELY 
c) DURATION OF HOSPITAL STAY 
d) LONGER 
  
9. In what type of surgery do you consider prescribing prophylactic beta blockers? (Choose any 
that apply) 
a) HIGH RISK (e.g. vascular, thoracic) 
b) MODERATE RISK (e.g., major orthopedic, abdominal) 
c) LOW RISK (e.g., cataract, peripheral) 
 
10. Does type of anesthesia influence your decision to use prophylactic beta blockers (i.e., 
general, regional, local)? 
a) YES 
b) NO 
 
11. When you use prophylactic beta blockers, what is your preferred drug? 
a) METOPROLOL 
b) ATENOLOL 
c) ESMOLOL 
d) OTHER  
 
12. Do you use perioperative a2 agonists (e.g., clonidine) in patients with risk factors or known 
cardio-vascular disease when beta blockers may be contraindicated? 
a) ALWAYS 
b) SOMETIMES 
c) NEVER 
 
13. Do you use a risk assessment tool to determine patient suitability for perioperative beta 
blocker therapy? 
a) ALWAYS 
b) FREQUENTLY 
c) OCCASIONALLY 
d) NEVER 
 
14. How long have you been practicing anesthesia? 
 a) 5 YEARS OR LESS 
 b) 5–10 YEARS 
 c) 10–15 YEARS 
 d) 15–20 YEARS 
e)> 20 YEARS 
 
15. What is your present age? 
a) Under 30 
b) 30–39 
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c) 40–49 
d) 50–59 
e) >60 
 
16. What is your gender? 
a) MALE 
b) FEMALE 
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Appendix C: Post-intervention Order Set 
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Appendix D: IRB Certificate 
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Appendix D: Pre-intervention Order Set  
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